TWC
NBIX icon

TD Waterhouse Canada’s Neurocrine Biosciences NBIX Stock Holding History

TD Waterhouse Canada’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-41
Closed -$5.64K – 1963
2024
Q1 		$5.64K Buy
+41
New +$5.6K ﹤0.01% 1510
2023
Q4 		– Sell
-19
Closed -$2.12K – 1771
2023
Q3 		$2.12K Hold
19
– – ﹤0.01% 1492
2023
Q2 		$1.79K Hold
19
– – ﹤0.01% 1549
2023
Q1 		$1.92K Hold
19
– – ﹤0.01% 1522
2022
Q4 		$2.28K Buy
+19
New +$2.23K ﹤0.01% 1470

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

TD Waterhouse Canada's NBIX Position: Q2 2024 in Review

TD Waterhouse Canada sold out of Neurocrine Biosciences (NBIX) in Q2 2024, closing a stake of 41 shares — an estimated $5.64K sold.

TD Waterhouse Canada first reported a position in NBIX in Q4 2022 and held it in 5 quarters. The position peaked at $5.64K in Q1 2024. 594 funds tracked by Wall St. Rank hold NBIX as of Q2 2024.

  • TD Waterhouse Canada reported no remaining Neurocrine Biosciences position as of Q2 2024 after selling out during the quarter.
  • TD Waterhouse Canada sold 41 Neurocrine Biosciences shares in Q2 2024, an estimated $5.64K.
  • TD Waterhouse Canada first reported a position in Neurocrine Biosciences in Q4 2022 and held it in 5 quarters.
  • TD Waterhouse Canada's Neurocrine Biosciences position peaked at $5.64K in Q1 2024.
  • 594 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2024.

Based on TD Waterhouse Canada's 13F filing for Q2 2024, filed 2 Aug 2024.